Clinical trials
Primary Hyperoxaluria Type 1 clinical trials
Below are recruiting primary hyperoxaluria type 1 clinical trials, each written for real people, not researchers. We’re tracking 8 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07776626RecruitingPhase 1
Phase I Exploratory Study of YOLT-203 in Patients With Primary Hyperoxaluria Type 1 (PH1)
Shanghai, Shanghai MunicipalityAges 6 years+ - NCT07587021RecruitingPhase 2
YOLT-203 treatment study for primary hyperoxaluria type 1
This study tests a new drug called YOLT-203 for people with primary hyperoxaluria type 1 (PH1), a rare genetic condition where the body produces too much oxalate, which can damage the kidneys. The trial aims to see if this drug can help reduce oxalate levels and prevent kidney damage.
Birmingham, AlabamaAges 6 years+ - NCT06511349RecruitingEarly Phase 1
YOLT-203 for type 1 primary hyperoxaluria (PH1)
This trial tests an experimental drug called YOLT-203 for people with type 1 primary hyperoxaluria (PH1), a rare condition that causes high oxalate levels and can damage the kidneys. It aims to see if YOLT-203 can safely help manage the disease.
Shanghai, Shanghai MunicipalityAges 2 years+ - NCT06225882Recruiting
Follow-up study for patients with primary hyperoxaluria type 1 on Lumasiran
This study follows patients with primary hyperoxaluria type 1 who are being treated with Lumasiran. It aims to understand how well the treatment works over time.
BesançonAges birth–99 years - NCT04580420RecruitingPhase 2
Study of an oxalate-lowering medicine for PH1 and kidney failure
This Phase 2 study tests a medicine called DCR-PHXC to lower body oxalate levels in people with PH1 who have advanced kidney failure. By lowering oxalate, the treatment may reduce harm from oxalate buildup and help researchers understand safety and effectiveness.
San Francisco, CaliforniaAges Any age - NCT06065852Recruiting
National registry for rare kidney diseases
This study creates a registry to collect health information from people with rare kidney diseases. It aims to improve understanding and future treatments by tracking patient experiences.
Bristol, South WestAges Any age - NCT06839235RecruitingPhase 1/Phase 2
Testing ABO-101 for primary hyperoxaluria type 1
This trial tests a new treatment called ABO-101 for people with primary hyperoxaluria type 1, a rare disease that causes high oxalate levels in urine. The study aims to see if ABO-101 can lower oxalate and protect kidney function.
Rochester, MinnesotaAges 6–64 - NCT02026388Recruiting
Kidney stone DNA and tissue sample biobank study
This study collects and stores donated samples (like blood, urine, and tissue) from people with certain rare inherited kidney stone conditions. The goal is to build a resource for future research that could help improve diagnosis and treatment.
Rochester, MinnesotaAges Any age
Hear when a new Primary Hyperoxaluria Type 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for primary hyperoxaluria type 1?
- Yes. Clin2 currently lists 8 recruiting primary hyperoxaluria type 1 studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a primary hyperoxaluria type 1 trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a primary hyperoxaluria type 1 trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.